South Korea · Delayed Price · Currency is KRW CTCBIO Statistics
Total Valuation
CTCBIO has a market cap or net worth of KRW 74.36 billion. The enterprise value is 96.47 billion.
| Market Cap | 74.36B |
| Enterprise Value | 96.47B |
Important Dates
The next estimated earnings date is Thursday, November 12, 2026.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CTCBIO has 23.91 million shares outstanding. The number of shares has increased by 0.59% in one year.
| Current Share Class | 23.91M |
| Shares Outstanding | 23.91M |
| Shares Change (YoY) | +0.59% |
| Shares Change (QoQ) | -0.47% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.09% |
| Float | 13.67M |
Valuation Ratios
The trailing PE ratio is 9.84.
| PE Ratio | 9.84 |
| Forward PE | n/a |
| PS Ratio | 0.57 |
| PB Ratio | 0.89 |
| P/TBV Ratio | 0.96 |
| P/FCF Ratio | 10.35 |
| P/OCF Ratio | 8.51 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.44, with an EV/FCF ratio of 13.42.
| EV / Earnings | 12.84 |
| EV / Sales | 0.73 |
| EV / EBITDA | 5.44 |
| EV / EBIT | 8.50 |
| EV / FCF | 13.42 |
Financial Position
The company has a current ratio of 1.72, with a Debt / Equity ratio of 0.48.
| Current Ratio | 1.72 |
| Quick Ratio | 1.00 |
| Debt / Equity | 0.48 |
| Debt / EBITDA | 2.27 |
| Debt / FCF | 5.61 |
| Interest Coverage | 4.95 |
Financial Efficiency
Return on equity (ROE) is 9.54% and return on invested capital (ROIC) is 9.80%.
| Return on Equity (ROE) | 9.54% |
| Return on Assets (ROA) | 4.79% |
| Return on Invested Capital (ROIC) | 9.80% |
| Return on Capital Employed (ROCE) | 10.81% |
| Weighted Average Cost of Capital (WACC) | 4.55% |
| Revenue Per Employee | 530.40M |
| Profits Per Employee | 30.30M |
| Employee Count | 248 |
| Asset Turnover | 0.89 |
| Inventory Turnover | 2.55 |
Taxes
In the past 12 months, CTCBIO has paid 1.16 billion in taxes.
| Income Tax | 1.16B |
| Effective Tax Rate | 13.27% |
Stock Price Statistics
The stock price has decreased by -56.01% in the last 52 weeks. The beta is 0.02, so CTCBIO's price volatility has been lower than the market average.
| Beta (5Y) | 0.02 |
| 52-Week Price Change | -56.01% |
| 50-Day Moving Average | 2,999.60 |
| 200-Day Moving Average | 3,870.93 |
| Relative Strength Index (RSI) | 53.23 |
| Average Volume (20 Days) | 52,448 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CTCBIO had revenue of KRW 131.54 billion and earned 7.51 billion in profits. Earnings per share was 313.12.
| Revenue | 131.54B |
| Gross Profit | 52.76B |
| Operating Income | 11.35B |
| Pretax Income | 8.74B |
| Net Income | 7.51B |
| EBITDA | 17.73B |
| EBIT | 11.35B |
| Earnings Per Share (EPS) | 313.12 |
Balance Sheet
The company has 22.83 billion in cash and 40.33 billion in debt, with a net cash position of -17.51 billion or -732.21 per share.
| Cash & Cash Equivalents | 22.83B |
| Total Debt | 40.33B |
| Net Cash | -17.51B |
| Net Cash Per Share | -732.21 |
| Equity (Book Value) | 83.43B |
| Book Value Per Share | 3,301.86 |
| Working Capital | 32.56B |
Cash Flow
In the last 12 months, operating cash flow was 8.74 billion and capital expenditures -1.55 billion, giving a free cash flow of 7.19 billion.
| Operating Cash Flow | 8.74B |
| Capital Expenditures | -1.55B |
| Depreciation & Amortization | 6.38B |
| Net Borrowing | 5.49B |
| Free Cash Flow | 7.19B |
| FCF Per Share | 300.58 |
Margins
Gross margin is 40.11%, with operating and profit margins of 8.63% and 5.71%.
| Gross Margin | 40.11% |
| Operating Margin | 8.63% |
| Pretax Margin | 6.64% |
| Profit Margin | 5.71% |
| EBITDA Margin | 13.48% |
| EBIT Margin | 8.63% |
| FCF Margin | 5.46% |
Dividends & Yields
CTCBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.59% |
| Shareholder Yield | -0.59% |
| Earnings Yield | 10.10% |
| FCF Yield | 9.67% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 22, 2013. It was a forward split with a ratio of 1.1.
| Last Split Date | Apr 22, 2013 |
| Split Type | Forward |
| Split Ratio | 1.1 |
Scores
CTCBIO has an Altman Z-Score of 2.01 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.01 |
| Piotroski F-Score | 6 |